Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Oct. 9, 2023

Abstract The use of nanotechnology has the potential to revolutionize detection and treatment cancer. Developments in protein engineering materials science have led emergence new nanoscale targeting techniques, which offer renewed hope for cancer patients. While several nanocarriers medicinal purposes been approved human trials, only a few authorized clinical cells. In this review, we analyze some formulations discuss challenges translating findings from lab clinic. This study highlights various compounds that can be used selective tumor inherent difficulties therapy. Nanotechnology provides promising platform improving future, but further research is needed overcome current limitations translation. Graphical

Language: Английский

---

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Advanced Materials, Journal Year: 2023, Volume and Issue: 35(51)

Published: May 17, 2023

Abstract Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to success coronavirus disease 2019 (COVID‐19) mRNA vaccines (Comirnaty Spikevax). To meet therapeutic purpose, it is required that must enter target cells express sufficient proteins. Therefore, development effective delivery systems necessary crucial. Lipid nanoparticle (LNP) represents a remarkable vehicle indeed accelerated applications humans, as several mRNA‐based therapies have already been approved or are clinical trials. In this review, focus on mRNA‐LNP‐mediated anticancer therapy. It summarizes main strategies mRNA‐LNP formulations, discusses representative approaches cancer, points out current challenges possible future directions research field. hoped these delivered messages can help further improve application technology cancer

Language: Английский

---

Ultrathin Clay Nanoparticles‐Mediated Mutual Reinforcement of Ferroptosis and Cancer Immunotherapy

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(9)

Published: Nov. 8, 2023

Ferroptosis-triggered immunogenic cell death (ICD) is widely adopted to potentiate the body's antitumor immunity by catalyzing production of toxic reactive oxygen species (ROS). However, efficacy ferroptosis and immunotherapy greatly restricted intracellular abundant glutathione (GSH) immunosuppressive tumor microenvironment (TME). Herein, a facile bottom-up method for solvent-free synthesis ultrathin manganese (Mn)-based layered double hydroxide nanosheets with high loading efficiency pro-inflammatory cytokine interferon (IFNγ) (IFNγ/uMn-LDHs) proposed mutually reinforce systemic immunity. The introduction ions significantly contributes GSH depletion hydroxyl radical generation, which can be further enhanced IFNγ delivery-induced SLC7A11 downregulation. ICD effect after cooperates intrinsic immunomodulatory property IFNγ/uMn-LDHs facilitate maturation dendritic cells (DCs) priming T cells. secretion from activated CD8

Language: Английский

---

Responsive biomaterials: optimizing control of cancer immunotherapy

Nature Reviews Materials, Journal Year: 2023, Volume and Issue: 9(2), P. 100 - 118

Published: Dec. 22, 2023

Language: Английский

---

An Engineered Nanoplatform with Tropism Toward Irradiated Glioblastoma Augments Its Radioimmunotherapy Efficacy

Advanced Materials, Journal Year: 2024, Volume and Issue: 36(32)

Published: May 7, 2024

Combining radiotherapy with immune checkpoint blockade therapy offers a promising approach to treat glioblastoma multiforme (GBM), yet challenges such as limited effectiveness and immune-related adverse events (irAEs) persist. These issues are largely due the failure in targeting immunomodulators directly tumor microenvironment. To address this, biomimetic nanoplatform that combines genetically modified mesenchymal stem cell (MSC) membrane bioactive nanoparticle core for chemokine-directed radioimmunotherapy of GBM is developed. The CC chemokine receptor 2 (CCR2)-overexpressing MSC acts tactical tentacle achieve radiation-induced tropism toward abundant (CC motif) ligand (CCL2) irradiated gliomas. core, comprising diselenide-bridged mesoporous silica nanoparticles (MSNs) PD-L1 antibodies (αPD-L1), enables X-ray-responsive drug release radiosensitization. In two murine models orthotopic tumors, this reinvigorated immunogenic death, augmented efficacy specificity radioimmunotherapy, reduced occurrence irAEs. This study suggests strategy targeted delivery, presents potent enhances safety radio-immunotherapy.

Language: Английский

---

An Intelligent Cupreous Nanoplatform with Self-Supplied H₂O₂ and Cu²⁺/Cu⁺ Conversion to Boost Cuproptosis and Chemodynamic Combined Therapy

Chemistry of Materials, Journal Year: 2024, Volume and Issue: 36(2), P. 815 - 828

Published: Jan. 11, 2024

Cuproptosis is a newly identified copper-dependent cell death and holds great promise for cancer therapy. However, transporting enough copper into cells challenge. Herein, an intelligent cupreous nanoplatform (denoted as CuO2-MSN@TA-Cu2+), consisting of in situ formation CuO2 within mesoporous silica nanoparticles (MSN) then deposition with tannic acid (TA)-Cu2+ complex, designed developed to realize on-demand delivery cuproptosis-based combination CuO2-MSN@TA-Cu2+ exhibits tumor microenvironment-triggered therapeutic activity, wherein the outer TA-Cu2+ complex readily disassembled release Cu2+ liberate internal produce H2O2. The overloaded can not only directly convert endogenous H2O2 self-supplied highly toxic hydroxyl radicals chemodynamic therapy (CDT) via Cu-based Fenton-like reaction but also undergo glutathione-mediated reduction Cu+ species induce potent cellular cuproptosis enhance CDT. experimental results indicate that produces remarkable cytotoxicity against significantly suppresses growth by 93.42% mice-bearing 4T1 breast tumors. This work provides new paradigm boost cuproptosis-related may inspire design advanced nanoplatforms.

Language: Английский

---

Self-Cascaded Pyroptosis-STING Initiators for Catalytic Metalloimmunotherapy

Journal of the American Chemical Society, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 17, 2025

Gasdermin (GSDM)-mediated pyroptosis involves the induction of mitochondrial damage and subsequent release DNA (mtDNA), which is anticipated to activate cGAS-STING pathway, thereby augmenting antitumor immune response. However, challenges lie in effectively triggering cancer cells subsequently enhancing activation with specificity. Herein, we developed intelligent self-cascaded pyroptosis-STING initiators cobalt fluoride (CoF2) nanocatalysts for catalytic metalloimmunotherapy. CoF2 a semiconductor structure enzyme-like activity generated substantial amount reactive oxygen species (ROS) under stimulation by endogenous H2O2 exogenous ultrasound. Importantly, discovered that Co-based nanomaterials themselves induce cells. Therefore, initially acted as inducers, caspase-1/GSDMD-dependent via Co2+ ROS, leading mtDNA release. Subsequently, were further utilized STING agonists specifically capable detecting pathway. These cascade events triggered robust response, modulating immunosuppressive tumor microenvironment into an immune-supportive state, providing favorable support therapy. This innovative strategy not only significantly impeded growth primary but also elicited response augment efficacy checkpoint inhibitors preventing distant progression. Overall, this study proposed self-cascade activating amplifying pathway specificity mediated pyroptosis, representing valuable avenue future

Language: Английский

---

Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy

Drug Delivery and Translational Research, Journal Year: 2023, Volume and Issue: 13(7), P. 2041 - 2056

Published: Feb. 25, 2023

Language: Английский

---

Immunostimulant Hydrogel-Guided Tumor Microenvironment Reprogramming to Efficiently Potentiate Macrophage-Mediated Cellular Phagocytosis for Systemic Cancer Immunotherapy

ACS Nano, Journal Year: 2023, Volume and Issue: 17(17), P. 17217 - 17232

Published: Aug. 16, 2023

Macrophage-mediated cellular phagocytosis (MMCP) plays a critical role in conducting antitumor immunotherapy but is usually impaired by the intrinsic evading ability of tumor cells and immunosuppressive microenvironment (TME). Herein, MMCP-boosting hydrogel (TCCaGM) was elaborately engineered encapsulating granulocyte-macrophage colony-stimulating factor (GM-CSF) therapeutic nanoplatform (TCCaN) that preloaded with tunicamycin (Tuni) catalase (CAT) assistance CaCO3 nanoparticles (NPs). Strikingly, hypoxic/acidic TME efficiently alleviated hydrogel, "eat me" signal calreticulin (CRT) upregulated, while "don't eat CD47 downregulated on cells, infiltrated DCs were recruited activated, all which contributed to boosting macrophage-mediated initiating tumor-specific CD8+ T responses. Meanwhile, remodeled beneficial accelerate polarization tumor-associated macrophages (TAMs) antitumoral M1-like phenotype, further heightening tumoricidal immunity. With combination PD-1 antibody (αPD-1), designed significantly heightened systemic immune responses long-term immunological effects control development primary distant tumors as well suppress metastasis recurrence, established an optimal strategy for high-performance immunotherapy.

Language: Английский

---

Liquid metal microspheres with an eddy-thermal effect for magnetic hyperthermia-enhanced cancer embolization-immunotherapy

Science Bulletin, Journal Year: 2023, Volume and Issue: 68(16), P. 1772 - 1783

Published: July 19, 2023

Language: Английский

---